Analyst Price Target is $10.75
▲ +208.91% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Acumen Pharmaceuticals in the last 3 months. The average price target is $10.75, with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 208.91% upside from the last price of $3.48.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Acumen Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Read More